sorafenib has been researched along with Thrombopenia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, Y; Huang, Z; Lan, R; Li, S; Long, Y; Song, X; Zhang, L | 1 |
| Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX | 1 |
| Bae, SH; Cheong, JY; Han, SY; Hwang, J; Kim, BH; Kim, DY; Kim, HY; Kim, YJ; Kwon, OS; Lee, HC; Lee, YJ; Paik, SW; Park, JW; Yeon, JE | 1 |
| Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A | 1 |
| Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C | 1 |
| Saif, MW | 1 |
| Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH | 1 |
| Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
2 review(s) available for sorafenib and Thrombopenia
| Article | Year |
|---|---|
Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Sorafenib; Thrombocytopenia; Treatment Outcome | 2023 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
3 trial(s) available for sorafenib and Thrombopenia
| Article | Year |
|---|---|
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperbilirubinemia; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Sorafenib; Thrombocytopenia | 2019 |
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; Humans; Hypokalemia; Hypophosphatemia; Liver Neoplasms; Male; Middle Aged; Sorafenib; Thrombocytopenia; Vorinostat | 2019 |
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Survival Rate; Thrombocytopenia; Young Adult | 2010 |
6 other study(ies) available for sorafenib and Thrombopenia
| Article | Year |
|---|---|
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
Rare complications of multikinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult | 2018 |
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Thyroidectomy | 2015 |
Platelet count less than SHARP: what does a case series reveal?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Platelet Count; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thrombocytopenia | 2010 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia | 2011 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |